InMed Pharmaceuticals (INM) said Tuesday that its INM-901 small molecule drug candidate for Alzheimer's disease reduced several plasma and brain markers of neuroinflammation in the trial.
The company said the study showed that INM-901 treated groups demonstrated a dose-dependent and statistically significant reduction in plasma pro-inflammatory cytokines and neurofilament light chain in the plasma for the high-dose treated group.
InMed also said the trial demonstrated a reduction of several key neuroinflammatory genes in the brain.
Shares of the company were up 43% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.